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Organ transplantation has evolved into a reliable life-
saving procedure where good organ function is quickly
restored by the transplant and, typically, the patient can
return to an active lifestyle. Unfortunately, the human
immune system reacts strongly against allogeneic tissues,
and will destroy a transplanted organ within days or
weeks after transplantation if the immune system is not
depleted or inhibited by immunosuppressive drugs. Near
elimination of the immune system through non-specific
[1] or specific depletive therapies [2] prior to transplant-
ation is one strategy that is effective at preventing early
reactions to the graft, and in a few cases in establishing
tolerance-promoting chimerism [3,4]. But these treat-
ments are harsh with significant side effects, and donor
tolerance is not assured after the immune system
recovers. Thus, the current standard of care for trans-
plant recipients involves the use of general immunosup-
pressive drugs that reduce graft destruction. The
downside of their use is that the whole immune system
is impaired, often causing a myriad of side-effects (for
example, toxicity, infection, and malignancy), and
chronic rejection remains a long-term problem. The lack
of improvement in 10-year organ survival rates over the
past decades for renal [5] and liver [6] transplantation
highlight the need for new therapeutic approaches to
prevent organ destruction.Cell therapy: The ONE Study focus
The ONE Study is the acronym for a large scale collab-
orative project funded by the European Community’s
FP7 [7]. The project is entitled: “A Unified Approach to
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reproduction in any medium, provided the orTransplantation” and involves scientists from Germany,
France, Italy, the United Kingdom and the United States
with the aim of improving treatment and the overall
quality of life for kidney transplant patients through cell
therapy. The goal of the project is to develop and test an
array of novel manufactured cell therapy products that
have promise to reduce a transplant patient’s life-long
dependency on immunosuppressive drugs. In principle,
the hypothesis behind cell therapy in the context of
organ transplantation is that treating recipients with a
concentrated dose of well-defined regulatory immune
cells near the time of transplantation will trigger a self-
sustaining immune regulation that establishes a level of
functional protection against allograft destruction. This
concept is fundamentally different from other modes of
treatment for transplant recipients since the therapy
supplements, or ‘adds-in’, a functional cellular compo-
nent of the immune system that is believed capable of
precipitating and establishing a protective immuno-
logical balance favoring allograft survival. In contrast, all
other current forms of therapy seek to take away im-
mune function through depletion of classes of detrimen-
tal immune cells, or through blockage of signals in these
cells required for immune reactions; this form of ‘func-
tionally inhibitory’ therapy primarily causes a general
suppression of the immune system.
The ONE Study consortium explores the feasibility
and potential of cell therapy in organ transplantation by
bringing together experts to test different regulatory cell
products composed of specific T cell (T regulatory cell,
Treg and T regulatory type 1 cell, Tr1 cell), dendritic
cell and macrophage subpopulations. While the primary
objective of the study is to perform a stringent side-by-
side comparison of these cell products using a single
(ONE) standardized trial protocol, a secondary aim is to
use this unique cooperative opportunity to experimen-
tally examine the immunoregulatory characteristics of
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To address the issue of comparing and contrasting sup-
pressive cell populations with cell therapy potential, a
series of investigative workshops have been planned
within the context of The ONE Study. The first of these
workshops has already taken place this year with an em-
phasis exclusively on producing and comparing suppres-
sive populations of cells derived from monocytes,
namely tolerogenic dendritic cells (tol DCs) [8],
myeloid-derived suppressor cells (MDSCs) [9], IL-10-
induced DCs (DC-10 cells) [10] and regulatory macro-
phages (M regs) [11,12]. A central premise of this work-
shop is that each cell type is produced side-by-side in a
single laboratory from the same leucapheresis products,
thus eliminating differences attributable to cell sources
and inter-laboratory conditions. This type of collabora-
tive effort is only possible through a large-scale integrat-
ing grant such as The ONE Study. While the final results
of this first workshop are still pending, the assembled
group of workshop participants decided it would be in-
formative to perform a separate review of each of the
monocyte-derived regulatory cell populations under
investigation.
In the current issue of Transplantation Research,
workshop participants present literature and their per-
spectives on the specific cell population that they pro-
duced for comparison. It is important to keep in mind
that the workshop investigators are studying the differ-
ent monocyte-derived regulatory cells more from a cell
production standpoint, versus taking a view towards nor-
mal physiological development. Indeed, the in vivo tem-
poral and complex signals directing a blood monocyte
or tissue macrophage to become activated, to take on
professional antigen-presenting functions, to migrate to
lymphoid structures, or to become suppressive, are not
fully understood. However, the workshop participants
primarily aim to distinguish or show similarities between
suppressive monocyte-derived cell populations that can
be generated under defined in vitro conditions. This is
an important undertaking since cell therapy applications
demand an ex vivo cultivation phase to manufacture a
homogenous and reproducible cell product.
For comparison, six cell populations were derived from
blood monocytes by investigators of the workshop
group: (1) tol DCs, (2) DC-10 cells, (3) rapamycin-
conditioned DCs (rapa DCs), (4) MDSCs, (5) M regs
and (6) monocytes conditioned with mesenchymal stem
cells (MSCs). The variety of stimuli that are considered
for cell production is especially evident with tol DCs.
The workshop group concentrated on tol DCs generated
under conditions including stimulation with low concen-
trations of GM-CSF [13], and with combinations of GM-
CSF, IL-4 and IL-10 (DC-10 cells [14]) or rapamycin
(rapa DCs [15]). Besides comparing the characteristics(gene expression, phenotype, function, etc.) of these
closely related cells to each other, they are comparable
to cells such as MDSCs, which can be generated under
similar conditions, but in the presence of prostaglandin
E2 [16] or other stimuli. Interestingly, to further show
the potential overlapping properties of monocyte-
derived suppressive cells, recent evidence suggests that
MSCs mediate their immunosuppressive effect through
induction of an auxiliary macrophage via IL-10 or pros-
taglandin E2 [17]; whether these conditioned macro-
phages are unique or similar to other suppressive
macrophages is a question to be addressed through the
workshop. Finally, our own group in Regensburg has
been actively studying the suppressive properties of
monocyte-derived cells generated through M-CSF-
induced maturation in combination with late ex vivo
interferon gamma stimulation (M regs [18]). While M
regs have a distinct phenotype compared to other known
suppressive macrophages [12], and have already been
used in a limited number of transplant recipients [11], it
remains unclear how these cells compare phenotypically
and functionally to ex vivo generated tol DCs or MDSCs;
The ONE Study workshop also seeks to answer this
question.
In preparing to assess the results of the first ONE
Study workshop on monocyte-derived suppressor cells,
the involved investigators deemed it useful to review the
present literature on tolerogenic DCs and macrophage/
myeloid derived suppressor cell populations. The
authors of the reviews consider the similarities and dif-
ferences of these closely related cell populations, and
suggest how they may best be applied as a cell therapy
meant to reduce organ transplant rejection. Indeed, cell
therapy is entering a critical early phase of testing in
transplantation, mandating that we take the necessary
steps to determine which cell populations are most
adaptable and effective for this purpose. The reviews in
this issue of Transplantation Research offer a view into
the future of cell therapy involving suppressive cells
derived from readily available circulating monocytes.
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